VTX-2337 is a small molecule Toll-like receptor 8 (TLR8) agonist that stimulates myeloid dendritic cells, monocytes, and enhances NK cell responses. It is administered subcutaneously on a weekly basis, and is currently in Phase I clinical development in oncology.

The ongoing clinical study of VTX-2337 is evaluating the safety, pharmacokinetics, and biological activity of this compound as a single agent, and is being conducted at two sites in the United States. We anticipate initiating a Phase II study in late 2010.

We anticipate VTX-2337 will be used clinically in combination with current standard-of-care treatments for cancer including monoclonal antibodies, chemotherapy and targeted therapies (e.g., kinase inhibitors).

For more information on the VTX-2337 clinical trial, please visit www.clinicaltrials.gov.